A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

American Journal of Psychiatry

Volumn 160, Issue 9, 2003, Pages 1651-1658

  Keck Jr , Paul E ^a   Marcus, Ronald ^b   Tourkodimitris, Stavros ^b   Ali, Mirza ^b   Liebeskind, Amy ^b   Saha, Anutosh ^b   Ingenito, Gary ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PLACEBO; PROLACTIN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE DISEASE; ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; BIPOLAR DISORDER; CHEMICALLY INDUCED DISORDER; EXTRAPYRAMIDAL SYNDROME; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIPERAZINES; PLACEBOS; QUINOLONES; TREATMENT OUTCOME;

EID: 0038585981     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.9.1651     Document Type: Article

References (34)

1. Keck PE Jr, Mendlwicz J, Calabrese JR, Fawcett J, Suppes T, Vestergaard PA, Carbonell C: A review of randomized, controlled clinical trials in acute mania. J Affect Disord 2000; 59(suppl 1):S31-S37
2. McElroy SL, Keck PE: Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48:539-557
3. Garfinkel PE, Stancer HC, Persad E: A comparison of haloperidol, lithium carbonate, and their combination in the treatment of mania. J Affect Disord 1980; 2:279-288
4. Prien RF, Caffey EM Jr, Klett CJ: Comparison of lithium carbonate and chlorpromazine in the treatment of mania: report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972; 26:146-153
5. Vestergarrd P: Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992; 7:249-259
6. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, Tollefson G: A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001; 65:85-93
7. Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62:22-31
8. Turrone P, Kapur S, Seeman MV, Flint AJ: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133-135
9. Glassman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774-1782
10. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW: An assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control. Br Med J 2002; 325:243
11. Henderson DC: Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77-89
12. Meyer JM: Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21:369-374
13. 2 receptors. J Pharmacol Exp Ther 2002; 302:381-389
14. Inoue T, Domae M, Yamada K, Furukawa T: Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277:137-143
15. 1A receptor. Eur J Pharmacol 2002; 441:137-140
16. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T: Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002; 5(suppl 1):S176
17. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res 2003; 61:123-136
18. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429-435
19. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159-171
20. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
21. Barnes TRE: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
22. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
23. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V (Olanzapine HGEH Study Group): Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702-709
24. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A (Olanzapine HGEH Study Group): Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57:841-849
25. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K (Ziprasidone in Mania Study Group): Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160:741-748
26. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63:207-213.
27. Ghaemi SN: New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry 2000; 61(suppl 14):33-42
28. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF: Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001; 62:273-281
29. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE: Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 2000; 61:179-184
30. Fagiolini A, Frank E, Houck PR, Mallinger A, Swartz H, Buysse DJ, Ombao H, Kupfer DJ: Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63:528-533
31. Carlsson A, Waters N, Waters S, Carlsson ML: Network interactions in schizophrenia - therapeutic implications. Brain Res Rev 2000; 31:342-349
32. Stahl SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001; 62:841-842
33. Stahl SM: Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001; 62:923-924
34. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771